Digital Marketing Company for Sale

Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System

Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System
Written by publishing team

COLLEGE STATION, TX / ACCESSWIRE / January 4, 2022 / Enzolytics, Inc. (OTC PINK: ENZC) ( reports the production and sale in the US and North America of “Enzolytics IPF Immune™”, a scientifically backed liquid nutritional supplement that boosts the body’s immune system. The immune modulator benefits the immune system by immunizing it against infections. The active ingredients in the supplement have been registered with the US Food and Drug Administration for use in the United States under an NDI registration. No. 1083, and the immune booster is produced and sold under the company’s exclusive license in North America under U.S. Patent No. 8,309,072 (Patent 072).

In addition to announcing these plans to start production of Enzolytics IPF Immune™, the company has engaged a National Marketing and Branding Agency as its distributor to develop the product through multiple distribution channels across the United States, and the company will benefit greatly from the agency’s extensive capacity to place this product in outlets. Major, big and small, across the country. In addition, the long-term presence and ability of the marketing agency in the industry is a great benefit to the company.

In the current ongoing pandemic, consumers are seeking any advantage to stay healthy. The coronavirus has forced many to reassess their health system. According to Grand View Research, the North American nutritional supplement market was $50.11 billion in 2020, and the projected revenue in 2028 is estimated at $77.1 billion. This annual increase led to record sales of immune-boosting supplements. In 2020, immune-boosting supplements set record sales, accounting for a third of sales of new nutritional supplements.

Increasing consumer awareness regarding personal health and well-being is one of the major drivers of the market. One in four US consumers started taking an immune supplement during the COVID-19 pandemic. Now, consumers will soon receive Enzolytics IPF Immune™, a scientifically backed immune modifier supplement.

The new product was produced under license to patent ‘072’, titled ‘Irreversibly inactivated pepsinogen fragments to modulate immune function’, a patent invented by the company’s chief scientific officer Harry Zapiloff.

This technique covers the use of irreversibly inactivated pepsin fragments (IPF) that have been shown in tests to perform an immune modulating function. The IPF core component is a complex platform that regulates the immune system and can be used alone or as an adjunct therapy for a variety of diseases. The active substance IPF in the product is derived from pepsin from the mucous membrane, and the method of its extraction and application is the subject of the licensed 072 patent. The immunomodulator consists of purified and lyophilized pepsin containing a polypeptide chain of 327 amino acid residues and a phosphoric acid residue. Using a special method, the peptide chain of 36 amino acids – (IPF) is isolated and made available in ready-to-use liquid form.

“Enzolytics IPF Immune strengthens your immune system,” said Charles Kotropia, CEO of Texas-based Enzolytics, Inc. It’s the daily supplement people have been looking for and needing during this health crisis. Enzolytics IPF Immune which has been in development since 2009, stimulates the body’s immune system to fight different types of infections. This is achieved by strengthening the body’s immune system against infections, helping it increase antibodies, promoting recovery and reducing the recovery period after illness.”

Enzolytics IPF Immune™ will be useful for those who have completed chemotherapy as it can be used after chemotherapy to aid recovery. “Our dietary supplement can reduce side effects after chemotherapy as well as promote recovery after completion of chemotherapy,” said Harry Zapiloff, CEO of the company and inventor of the 072 Patent Covers product. This immune modulator does not produce the side effects or toxicity that often come from using other antivirals. Mr. Zapilov added that the product provides significant health benefits in an easy-to-use liquid form to be taken orally.

Enzolytics Inc. is a Texas-based biotechnology company focused on treatments to treat many medical conditions for human health. In addition to Enzolytics IPF Immune™, which is now coming to market in the United States, the company is working to produce other treatments to treat many infectious diseases, such as COVID-19, HIV and cancer. “We have a research team that has more than 40 years of experience in developing human health therapies,” said Mr. Kotropia, adding that the company holds several US patents and patent applications pending on therapeutic products.

About Enzolytics, Inc.
Enzolytics, Inc. is a pharmaceutical development company committed to commercializing its own proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The company is developing multiple treatments that target many infectious diseases. One of the patented and clinically tested compounds, ITV-1 (immunotherapy vaccine-1), is an inactivated pepsin fraction (IPF) suspension, covered by US Patents Nos. 8066982 and 7479.538. Studies have shown that it is effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.

The company also applies its own technology to produce all-human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus and diphtheria. Its proprietary methodology, which is covered in a pending US patent application for the production of all-human monoclonal antibodies, is currently used to produce monoclonal antibody treatments for many infectious diseases, including SARS-CoV-2 and HTLV. -1.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties relating to financial projections, budgets, major timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. From time to time in its periodic reports filed with the SEC. ITV-1 has not been approved by the US Food and Drug Administration or by any similar regulatory bodies anywhere else in the world.

While Enzolytics, Inc. that the forward-looking statements and the underlying assumptions made therein are reasonable, then any of the assumptions may be inaccurate, including, without limitation, the ability of Enzolytics to demonstrate the effectiveness of its treatments in the treatment of any disease or health condition, and to develop studies and strategies that lead to the commercialization of its treatments In the United States, obtain the funding required to implement the development plan, complete the studies and tests on time or at all, and succeed the results of these studies or tests. Therefore, there can be no guarantee that the forward-looking statements made in this release will prove to be accurate.

These forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, misrepresent, or alter any data provided, and cause actual results and outcomes to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or to update the reasons why actual results may differ from those projected in the forward-looking statements.

IR contact:
TEN Associates, LLC
Tom Nelson, CEO
(480) 326-8577

Investor Relations Contact

Company contact:
Enzolytics, Inc.
2000 North Central Highway
Plano, TX 75074


Research Center
Enzolytics, Inc.
Texas A&M University

Institute of Preclinical Studies
College Station, TX 77843-44

source: Enzolytics, Inc.

View the source version on immune system

About the author

publishing team